PMID- 2943286
OWN - NLM
STAT- MEDLINE
DCOM- 19860917
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 35
IP  - 16
DP  - 1986 Aug 15
TI  - Effects of cerebro-protective agents on enzyme activities of rat primary glial 
      cultures and rat cerebral cortex.
PG  - 2693-702
AB  - The effects of different cerebro-protective agents on selected key enzymes of the 
      energy metabolism of rat primary glial cultures and rat cerebral cortex were 
      studied. As indicators for the capacity of the most important pathways of energy 
      metabolism the following enzyme activities were determined: hexokinase (HK), 
      phosphofructokinase (PFK), pyruvate kinase (PK), lactate dehydrogenase (LDH), 
      glucose-6-phosphate dehydrogenase (G-6-P-DH), malate dehydrogenase (MDH), 
      glutamate dehydrogenase (GDH), and cytochrome-c-reductase (CCR). After a one week 
      growth period, rat glial cultures were incubated for 3 or 4 weeks with the 
      substances to be tested. Bencyclane (5 X 10(-5) mol/l) increased the activities 
      of HK, G-6-P-DH, and LDH, whereas PFK and CCR were reduced. Pyritinol (10(-4) 
      mol/l) led to a higher G-6-P-DH activity, simultaneously lowering the values for 
      PFK, CCR, PK, LDH, and MDH. Under the influence of an extract of the leaves of 
      Ginkgo bilobae (EGB; 100 mg/l) PFK, LDH, and MDH activities were reduced. All 
      these alterations in enzyme activities went along with simultaneous reductions in 
      protein content, therefore not allowing to exclude toxic effects with regard to 
      the doses used. Moreover, direct interference with the analytical procedure was 
      demonstrable for bencyclane and EGB. Piracetam (10(-3) mol/l), flunarizine 
      (10(-6) mol/l), dihydroergocristine (5 X 10(-6) mol/l), and nicergoline (5 X 
      10(-6) mol/l) failed to induce any alteration in the employed doses. The most 
      striking effects were obtained with meclofenoxate which was tested at 10(-3) and 
      10(-4) mol/l. The higher dose caused an elevation of HK, PFK, CCR, G-6-P-DH, GDH 
      and MDH activities, while slightly reducing PK. With the lower dose of 
      meclofenoxate CCR and G-6-P-DH activities were increased. Short-term incubation 
      of the cultures with 10(-3) mol/l meclofenoxate for 24 hr led to an increase in 
      LDH, G-6-P-DH, and GDH activities. Chronic incubation with meclofenoxate (10(-3) 
      mol/l) followed by 48 hr deprivation of the drug resulted in elevated HK, PFK, 
      CCR, G-6-P-DH, GDH, and MDH activities. These changes were accompanied by 
      alterations in related metabolite levels. These include elevations in the 
      concentration of creatine phosphate and fructose-1,6-bisphosphate, whereas 
      glucose-6-phosphate levels were reduced. After one week of meclofenoxate 
      deprivation the activities of CCR and G-6-P-DH were still elevated. The 
      metabolites of meclofenoxate dimethylaminoethanol (DMAE; 10(-3) mol/l) and 
      p-chlorophenoxyacetic acid (10(-3) mol/l) were also investigated.(ABSTRACT 
      TRUNCATED AT 400 WORDS)
FAU - Bielenberg, G W
AU  - Bielenberg GW
FAU - Hayn, C
AU  - Hayn C
FAU - Krieglstein, J
AU  - Krieglstein J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Isoenzymes)
RN  - 0 (Plant Extracts)
RN  - 2577AQ9262 (2,4-Dichlorophenoxyacetic Acid)
RN  - 2N6K9DRA24 (Deanol)
RN  - 4EMM3U5P3K (4-chlorophenoxyacetic acid)
RN  - 6I97Z6S135 (Bencyclane)
RN  - AK5Q5FZH2R (Pyrithioxin)
RN  - C76QQ2I0RG (Meclofenoxate)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 1.1.1.37 (Malate Dehydrogenase)
RN  - EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
RN  - EC 1.4.1.2 (Glutamate Dehydrogenase)
RN  - EC 1.6.99.3 (NADH Dehydrogenase)
RN  - EC 2.7.1.1 (Hexokinase)
RN  - EC 2.7.1.11 (Phosphofructokinase-1)
RN  - EC 2.7.1.40 (Pyruvate Kinase)
SB  - IM
MH  - 2,4-Dichlorophenoxyacetic Acid/analogs & derivatives/pharmacology
MH  - Animals
MH  - Bencyclane/pharmacology
MH  - Cerebral Cortex/drug effects/*enzymology
MH  - Deanol/pharmacology
MH  - Energy Metabolism/drug effects
MH  - Glucosephosphate Dehydrogenase/metabolism
MH  - Glutamate Dehydrogenase/metabolism
MH  - Hexokinase/metabolism
MH  - Isoenzymes
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Malate Dehydrogenase/metabolism
MH  - Male
MH  - Meclofenoxate/pharmacology
MH  - NADH Dehydrogenase/metabolism
MH  - Neuroglia/drug effects/*enzymology
MH  - Phosphofructokinase-1/metabolism
MH  - Plant Extracts/pharmacology
MH  - Pyrithioxin/pharmacology
MH  - Pyruvate Kinase/metabolism
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Trees
EDAT- 1986/08/15 00:00
MHDA- 2000/06/01 09:00
CRDT- 1986/08/15 00:00
PHST- 1986/08/15 00:00 [pubmed]
PHST- 2000/06/01 09:00 [medline]
PHST- 1986/08/15 00:00 [entrez]
AID - 0006-2952(86)90177-2 [pii]
AID - 10.1016/0006-2952(86)90177-2 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1986 Aug 15;35(16):2693-702. doi: 
      10.1016/0006-2952(86)90177-2.